" he certainly did not think Roche would continue selling Tamiflu once its patent expires..."
When I asked PC if Relenza would be the major competitor to Lani after Relenza patent expires, I think his answer was that Relenza would not be the major competing product to Lani, but Tamiflu would be.
So, if Roche would not continue selling Tamiflu, then how could he say that Tamiflu would be the major competing product to Lani? He meant generic Tamiflu?
I think the reason given by PC that big pharmas do not like influenza antiviral products is that flu antiviral product market is very unstable and hence unpredictable, and big pharmas like more predictable markets.
Is my understanding wrong?
BTA Price at posting:
80.0¢ Sentiment: Hold Disclosure: Held
